NEGR1 and early-onset autosomal dominant Alzheimer disease: Figure 7 provides a graphical illustration of the functions of IgLON4 in SM. IgLON4 has recently been investigated as a therapeutic target in numerous disease settings, including obesity, intellectual disability, schizophrenia, depression, and Alzheimer’s disease [1]. IgLON4 gene knockout mice exhibited substantial increases in fat mass and significant decreases in muscle mass, which suggests IgLON4 ought to be considered a potential molecular target for the development of anti-obesity therapies [20].